A quality defect of the NETSPOT product was identified – stability test results showed the content of the active substance DOTATATE close to the lower limit of the specification, meaning that established quality requirements are not met. Potential effects: lack of diagnostic efficacy, risk of delayed disease diagnosis.
Download the app and stay informed
Get instant notifications about recalled products and protect your family.
Important Information
Do not use batches PG1921019 and PG1921020. Check the batch number of the product in possession and, if it matches, return it to the dispensing entity and consult a physician regarding further managem...
The Chief Pharmaceutical Inspector withdrew NETSPOT batches PG1921019 and PG1921020 from the market throughout the country and granted the decision immediate enforceability, obliging the marketing aut...
If you feel unwell after consuming this product, contact your doctor or call the poison control center.
FAQ
Related